

COVID19 #ClinicalTrial #Treatment #PolyclonalAntibodies

XENOTHERA's anti-COVID XAV-19 treatment: Completion of patients' enrolment in the POLYCOR clinical trial promoted by the Nantes University Hospital

Nantes, April 21, 2021 - The biotech company [XENOTHERA](#) and [the Nantes University Hospital](#) announce the end of enrolment in the second phase of the POLYCOR clinical trial, promoted by the Nantes University Hospital and [labelled a National Research Priority by the CAPNET inter-ministerial committee](#). 398 patients were included in this study which evaluates the efficacy of XAV-19 in patients with moderate COVID-related pneumonia. XAV-19 is a specific polyclonal antibody developed by XENOTHERA aimed at stopping the worsening of the disease and avoiding in particular a transfer to intensive care unit. The engagement of a network of 35 hospitals* in France has enabled the POLYCOR study to reach its inclusion target in less than three months. The first results of the trial are expected in the summer.

"We are very pleased to have been able to finalize enrolment in such a short time frame and would like to thank the patients as well as all our colleagues and the clinical research units of all hospitals involved in this important study. We would like to thank the patients and all our colleagues and clinical research units involved in this important study," said **Dr. Benjamin Gaborit, POLYCOR Coordinating Investigator from the Department of Infectious and Tropical Diseases at the University Hospital of Nantes.**

"In total, the end of POLYCOR's inclusions comes one year to the day after our first meeting with the ANSM, in full confinement, on 16 April 2021. The extraordinary speed at which this project is being carried out is the result of an exceptional momentum of the teams and of the very high-quality collaboration between the Nantes University Hospital and our biotech, in an emergency context. Everyone involved has done an incredible job; it's great!" commented **Dr Odile Duvaux, President of XENOTHERA.**

XENOTHERA's drug candidate XAV-19 is a **protective anti-SARS-CoV-2 polyclonal antibody similar to the natural human response**. Based on a unique and patented proprietary technology, it acts through several mechanisms of action, including neutralizing the virus, reducing inflammation and limiting the risk of cytokine storms.

At the same time, **the Nantes University Hospital, XENOTHERA, and Professor Vincent Calvez's team at the Pitié Salpêtrière Hospital signed two major publications demonstrating the efficacy of XAV-19 on the variants** ([Vanhove B. et al. BioRxiv, 2021](#)) and sharing the first clinical results from phase IIa ([Gaborit B. et al. MedRxiv, 2021](#)).

XAV-19 is currently one of the most promising anti-COVID antibodies in development.

***List of the 35 French hospitals that participated in the POLYCOR trial:**

Centre n°1 : CHU de Nantes
Centre n°2 : AP-HP Hôpital Saint Antoine - Paris
Centre n°3 : CHU Angers
Centre n°4 : Hospices Civils de Lyon
Centre n°5 : CHD Vendée – La Roche sur Yon
Centre n°6 : CHU de Limoges
Centre n°7 : CH Mont de Marsan
Centre n°8 : CH Bayonne
Centre n°9 : CH La Rochelle
Centre n°10 : CHU de Caen
Centre n°11 : Hôpital Privé d'Antony
Centre n°12 : CHU d'Amiens
Centre n°13 : CHU de Reims
Centre n°14 : Hospices Civils de Colmar
Centre n°15 : CH Le Mans
Centre n°16 : CH de Chambéry
Centre n°17 : CH de Quimper
Centre n°18 : CHU de Nîmes
Centre n°19 : Hôpital Foch (Suresnes)
Centre n°20 : CHU Fort de France
Centre n°21 : CHU La Réunion Nord
Centre n°22 : CHU La Réunion Sud
Centre n°23 : CH d'Avignon
Centre n°24 : CHU de Lille
Centre n°25 : Corbeil-Essonnes
Centre n°26 : CHU de Nice
Centre n°27 : CH de Pontoise
Centre n°28 : CHU de Saint Etienne
Centre n°29 : CHR d'Orléans
Centre n°30 : Hôpitaux Universitaires de Strasbourg
Centre n°31 : CHU de Nancy
Centre n°32 : CH de Vannes
Centre n°33 : AP-HP Hôpital Avicenne
Centre n°34 : CH de Mulhouse
Centre n°35 : AP-HP Hôpital Tenon

About POLYCOR:

POLYCOR is a French phase 2/3 clinical trial measuring the safety and efficacy of XAV-19 in patients with moderate COVID-19. It is led by Dr Benjamin Gaborit, and Professor François Raffi of the Nantes University Hospital. POLYCOR is funded as a collaborative project involving Nantes University Hospital, the University of Nantes and XENOTHERA. It has received a grant of €8.3 million from the General Secretariat for Investment in the form of a PSPC COVID.

About XENOTHERA:

Founded in 2014, XENOTHERA is a Nantes-based biotech company that develops "glyco-humanized" polyclonal antibodies. Its technological platform is built on a dual expertise in genetics and immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant in transplantation, has been in the clinic since 2019. XENOTHERA has also been developing its treatment for

coronavirus infections for several years. XAV-19 is XENOTHERA's treatment for patients at the beginning of hospitalization, it is based on a unique patented antibody production technology, developed and proven for several years by the biotech.

XENOTHERA, a member of the Atlanpole Biotherapies competitiveness cluster, is part of the scientific and medical environment of the Pays de la Loire. The company has been supported since its creation by private investors, by the Pays de la Loire Region and by BPI France. Since its creation, the company has raised more than 23 million euros to finance all of its products.

For more information: www.xenothera.com

Follow XENOTHERA on social networks: [LinkedIn](#) [Twitter](#)

About Nantes University Hospital:

Nantes University Hospital is the sixth largest hospital in France and has a triple mission of care, teaching and research. It employs more than 12,500 medical and paramedical professionals, making it the largest employer in the Pays-de-la-Loire region.

By treating the most serious conditions and providing the most complex treatments, it is a centre of excellence, a referral centre and a reference centre at regional and interregional level, while providing routine and local care for the 800,000 inhabitants of the Nantes/Saint-Nazaire metropolitan area.

The Nantes University Hospital is ranked nationally among the "strong researcher" establishments, with 26 clinical investigation units, more than 2,100 active protocols and more than 1,200 publications per year.

More information : <https://www.chu-nantes.fr/>

Medias relations:

IZsoGOOD

Ingrid Zémor & Elise Plat

+33(6) 73 72 99 92 / +33(6) 79 98 48 94

xenothera@izsoqood.co